Candel Therapeuitcs CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to share the company's cutting-edge advancements in viral therapies targeting difficult-to-treat cancers such as prostate, pancreatic, and brain cancers. Candel’s lead compound leverages an innovative in situ vaccination approach, enabling the patient’s immune system to combat both local tumors and distant metastases. With two large randomized prostate cancer trials set to deliver results by year-end, this represents a significant opportunity to address unmet medical needs.
Dr. Tak also highlighted the potential of CAN-3110, an engineered herpes simplex virus aimed at treating glioblastoma, with new data on serial injections to be unveiled at an upcoming international conference. The therapy shows promise for expansion into melanoma and other cancers. He noted that positive trial outcomes could lead to regional partnerships to accelerate global patient access. Looking ahead, Candel anticipates further data from its pipeline, particularly in pancreatic and lung cancers, by early 2024.
Dr. Tak emphasized the company’s strategic focus on partnerships to scale its operations, positioning Candel Therapeutics (NASDAQ:CADL) for significant growth and a potential transformation into a broader pharmaceutical player over the next six months.